PL1964852T3 - Przeciwciało anty-ilt7 - Google Patents

Przeciwciało anty-ilt7

Info

Publication number
PL1964852T3
PL1964852T3 PL06842945T PL06842945T PL1964852T3 PL 1964852 T3 PL1964852 T3 PL 1964852T3 PL 06842945 T PL06842945 T PL 06842945T PL 06842945 T PL06842945 T PL 06842945T PL 1964852 T3 PL1964852 T3 PL 1964852T3
Authority
PL
Poland
Prior art keywords
ilt7 antibody
ilt7
antibody
Prior art date
Application number
PL06842945T
Other languages
English (en)
Polish (pl)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of PL1964852T3 publication Critical patent/PL1964852T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
PL06842945T 2005-12-20 2006-12-20 Przeciwciało anty-ilt7 PL1964852T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
PCT/JP2006/325391 WO2007072866A1 (ja) 2005-12-20 2006-12-20 抗ｉｌｔ７抗体
EP06842945.5A EP1964852B1 (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Publications (1)

Publication Number Publication Date
PL1964852T3 true PL1964852T3 (pl) 2013-09-30

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06842945T PL1964852T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ilt7
PL12168586T PL2532681T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ILT7
PL14186905T PL2913343T3 (pl) 2005-12-20 2006-12-20 Przeciwciało przeciw ilt7

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12168586T PL2532681T3 (pl) 2005-12-20 2006-12-20 Przeciwciało anty-ILT7
PL14186905T PL2913343T3 (pl) 2005-12-20 2006-12-20 Przeciwciało przeciw ilt7

Country Status (29)

Country Link
US (6) US8084585B2 (enExample)
EP (4) EP2532681B1 (enExample)
JP (2) JP5020828B2 (enExample)
KR (3) KR101624587B1 (enExample)
CN (5) CN120718150A (enExample)
AU (1) AU2006328470B2 (enExample)
BR (1) BRPI0620141B1 (enExample)
CA (2) CA2994756C (enExample)
CY (3) CY1114227T1 (enExample)
DK (3) DK2532681T3 (enExample)
ES (3) ES2699428T3 (enExample)
HK (1) HK1218126A1 (enExample)
HR (2) HRP20130494T1 (enExample)
HU (1) HUE039865T2 (enExample)
IL (1) IL192266A (enExample)
LT (1) LT2913343T (enExample)
ME (1) ME02111B (enExample)
MX (1) MX2008007682A (enExample)
NZ (3) NZ599683A (enExample)
PL (3) PL1964852T3 (enExample)
PT (3) PT1964852E (enExample)
RS (2) RS53752B1 (enExample)
RU (2) RU2456298C2 (enExample)
SG (2) SG10201602095PA (enExample)
SI (3) SI2913343T1 (enExample)
TR (1) TR201816574T4 (enExample)
UA (1) UA97946C2 (enExample)
WO (1) WO2007072866A1 (enExample)
ZA (1) ZA200805850B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
SG10201501342UA (en) * 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
SI2694106T1 (en) 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer
SI2828284T1 (sl) 2012-03-20 2019-10-30 Biogen Ma Inc Virus JC nevtralizirajoča protitelesa
ES2706173T3 (es) * 2012-03-20 2019-03-27 Biogen Ma Inc Anticuerpos de neutralización de JCV
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CA3222465A1 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
RU2016129744A (ru) * 2013-12-24 2018-01-30 Астеллас Фарма Инк. Новое антитело против bdca-2 человека
IL278574B2 (en) 2014-11-12 2024-11-01 Seagen Inc Glycan-interacting compounds and methods of use
DK3270965T3 (da) * 2015-03-18 2020-06-08 Seattle Genetics Inc Cd48-antistoffer og konjugater deraf
BR112017027254A2 (pt) * 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
BR112018010279A2 (pt) * 2015-11-19 2019-02-05 Abbvie Stemcentrx Llc novos anticorpos anti-emr2 e métodos de uso
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. Automated dental treatment system
WO2017132486A1 (en) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
MX2018010445A (es) * 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
KR102802736B1 (ko) * 2016-03-10 2025-05-02 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
EP3675898A4 (en) * 2017-08-30 2021-09-01 Phanes Therapeutics, Inc. ANTI-LAG-3 ANTIBODIES AND THEIR USES
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
JOP20200131A1 (ar) * 2017-11-17 2020-05-28 Merck Sharp & Dohme أجسام مضادة خاصة بنسخة تشبه جلوبيولين مناعي 3 (ilt3) واستخدامتها
CA3086009A1 (en) * 2017-12-20 2019-06-27 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
WO2019215512A1 (en) 2018-05-10 2019-11-14 Cyberdontics Inc. Automated dental drill
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
KR20220116575A (ko) 2019-08-12 2022-08-23 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
AU2020395232A1 (en) * 2019-12-06 2022-07-14 Viela Bio, Inc. Methods of treatment using ILT7 binding proteins
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof
EP4208122A4 (en) 2020-09-03 2024-09-11 Perceptive Technologies, Inc. METHOD AND DEVICE FOR CNA ANALYSIS OF DENTAL ANATOMY
CA3217278A1 (en) * 2021-05-04 2022-11-10 William Rees Methods of treatment of autoimmune disorders using ilt7 binding proteins
CN119630703A (zh) 2022-07-27 2025-03-14 维埃拉生物股份有限公司 包含免疫球蛋白样转录物7（ilt7）结合蛋白的配制剂
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
KR20250160358A (ko) * 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
WO2003012061A2 (en) 2001-08-01 2003-02-13 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
WO2003034275A2 (en) * 2001-10-13 2003-04-24 Asterion Limited Chimeric glycosylphosphatidylinositol containing peptides
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
SG10201602095PA (en) 2016-05-30
AU2006328470B2 (en) 2012-08-16
HK1218126A1 (zh) 2017-02-03
EP1964852A4 (en) 2010-02-24
CY1116031T1 (el) 2017-01-25
EP2532681B1 (en) 2014-10-01
NZ599683A (en) 2013-11-29
CA2634116C (en) 2018-03-27
RU2012112046A (ru) 2013-10-10
CN120718150A (zh) 2025-09-30
EP2532681A1 (en) 2012-12-12
IL192266A (en) 2014-09-30
KR20140053232A (ko) 2014-05-07
CA2994756C (en) 2020-10-27
HK1214603A1 (en) 2016-07-29
BRPI0620141A2 (pt) 2011-11-01
KR101585532B1 (ko) 2016-01-14
TR201816574T4 (tr) 2018-11-21
US20170204179A1 (en) 2017-07-20
KR20150031485A (ko) 2015-03-24
PT2532681E (pt) 2014-12-23
KR20080090430A (ko) 2008-10-08
US20130259872A1 (en) 2013-10-03
US20160130343A1 (en) 2016-05-12
PL2913343T3 (pl) 2019-03-29
NZ616992A (en) 2015-07-31
CN110776566B (zh) 2025-07-15
CN103360492A (zh) 2013-10-23
HUE039865T2 (hu) 2019-02-28
EP3441403A1 (en) 2019-02-13
NZ569910A (en) 2012-06-29
HK1124347A1 (en) 2009-07-10
CN101379089B (zh) 2013-08-07
DK1964852T3 (da) 2013-07-08
EP2913343B1 (en) 2018-08-08
CN105111311A (zh) 2015-12-02
LT2913343T (lt) 2018-11-26
IL192266A0 (en) 2008-12-29
CN110776566A (zh) 2020-02-11
PT1964852E (pt) 2013-07-10
BRPI0620141B1 (pt) 2024-04-30
EP1964852A1 (en) 2008-09-03
EP2913343A1 (en) 2015-09-02
DK2532681T3 (en) 2015-01-05
JP2012143232A (ja) 2012-08-02
CA2994756A1 (en) 2007-06-28
RU2456298C2 (ru) 2012-07-20
JPWO2007072866A1 (ja) 2009-06-04
ES2526079T3 (es) 2015-01-05
ME02111B (me) 2015-10-20
US20120135003A1 (en) 2012-05-31
SG170749A1 (en) 2011-05-30
ES2699428T3 (es) 2019-02-11
DK2913343T3 (en) 2018-11-26
CN101379089A (zh) 2009-03-04
SI2532681T1 (sl) 2015-03-31
WO2007072866A1 (ja) 2007-06-28
ZA200805850B (en) 2009-04-29
RS53752B1 (sr) 2015-06-30
HRP20141226T1 (hr) 2015-02-27
EP1964852B1 (en) 2013-04-17
US8084585B2 (en) 2011-12-27
RU2008129715A (ru) 2010-01-27
HK1179638A1 (en) 2013-10-04
PT2913343T (pt) 2018-11-21
CY1114227T1 (el) 2016-08-31
CN105111311B (zh) 2019-10-18
AU2006328470A2 (en) 2008-10-09
AU2006328470A1 (en) 2007-06-28
MX2008007682A (es) 2008-10-23
UA97946C2 (ru) 2012-04-10
US20200339682A1 (en) 2020-10-29
US8470992B2 (en) 2013-06-25
CY1121294T1 (el) 2020-05-29
CA2634116A1 (en) 2007-06-28
JP5020828B2 (ja) 2012-09-05
RU2599450C2 (ru) 2016-10-10
SI2913343T1 (sl) 2019-01-31
ES2416716T3 (es) 2013-08-02
SI1964852T1 (sl) 2013-09-30
US20090280128A1 (en) 2009-11-12
KR101526934B1 (ko) 2015-06-26
RS52860B (sr) 2013-12-31
KR101624587B1 (ko) 2016-05-26
JP5420688B2 (ja) 2014-02-19
HRP20130494T1 (en) 2013-08-31
PL2532681T3 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL192266A0 (en) Anti-ilt7 antibody
IL185366A0 (en) Antibody
SG10201404801YA (en) Monoclonal antibody
IL181575A0 (en) Anti-ox40l antibodies
IL185380A0 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
IL228033A0 (en) Antibodies
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
GB0615662D0 (en) Antibody
GB0420466D0 (en) Anti-glucan antibodies
GB0517487D0 (en) Antibodies
ZA200701952B (en) Anti-OX40L antibodies
IL215528A (en) Methods will notice training
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0418415D0 (en) Antibody
GB0505054D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0500400D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies
ZA200709879B (en) Improved immunoassay methods
GB0402641D0 (en) Antibodies